GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Citius Pharmaceuticals Inc (NAS:CTXR) » Definitions » Total Equity

Citius Pharmaceuticals (Citius Pharmaceuticals) Total Equity : $79.97 Mil (As of Mar. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Citius Pharmaceuticals Total Equity?

Citius Pharmaceuticals's total equity for the quarter that ended in Mar. 2024 was $79.97 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.


Citius Pharmaceuticals Total Equity Historical Data

The historical data trend for Citius Pharmaceuticals's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Citius Pharmaceuticals Total Equity Chart

Citius Pharmaceuticals Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 27.15 33.67 132.78 103.43 91.43

Citius Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 91.81 98.30 91.43 85.34 79.97

Citius Pharmaceuticals Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Citius Pharmaceuticals's Total Equity for the fiscal year that ended in Sep. 2023 is calculated as

Total Equity=Total Assets(Q: Sep. 2023 )-Total Liabilities(Q: Sep. 2023 )
=103.611-12.18
=91.43

Citius Pharmaceuticals's Total Equity for the quarter that ended in Mar. 2024 is calculated as

Total Equity=Total Assets(Q: Mar. 2024 )-Total Liabilities(Q: Mar. 2024 )
=90.711-10.744
=79.97

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Citius Pharmaceuticals Total Equity Related Terms

Thank you for viewing the detailed overview of Citius Pharmaceuticals's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Citius Pharmaceuticals (Citius Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
11 Commerce Drive, First Floor, Cranford, NJ, USA, 07016
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma . Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome.
Executives
Myron Z Holubiak director, officer: Vice Chairman C/O CITIUS PHARMACEUTICALS, INC., 63 GREAT ROAD, MAYNARD MA 01754
Dennis M Mcgrath director C/O PAVMED INC., ONE GRAND CENTRAL PLACE, STE. 4600, NEW YORK NY 10165
Leonard L Mazur director, 10 percent owner, officer: Chief Executive Officer C/O CITIUS PHARMACEUTICALS, INC., 11 COMMERCE DRIVE, 1ST FLOOR, CRANFORD NJ 07016
Suren G Dutia director C/O CITIUS PHARMACEUTICALS, INC., 63 GREAT ROAD, MAYNARD MA 01754
Carol Webb director 11 COMMERCE DRIVE, FIRST FLOOR, CRANFORD NJ 07016
Eugene Myron Holuka director 11 COMMERCE DRIVE, 11TH FLOOR, CRANFORD NJ 07016
Jaime Bartushak officer: Chief Financial Officer C/O CITIUS PHARMACEUTICALS, INC., 11 COMMERCE DRIVE, 1ST FLOOR, CRANFORD NJ 07016
Myron Czuczman officer: Chief Medical Officer C/O CITIUS PHARMACEUTICALS, INC., 11 COMMERCE DRIVE, 1ST FLOOR, CRANFORD NJ 07016
Howard Safir director 11 COMMERCE DRIVE, FIRST FLOOR, CRANFORD NJ 07016
William Kane director 11 COMMERCE DRIVE, FIRST FLOOR, CRANFORD NJ 07016